{"groups":[{"description":"Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"FG000","title":"Dose Escalation Cohort 1: RO7297089"},{"description":"Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"FG001","title":"Dose Escalation Cohort 2: RO7297089"},{"description":"Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"FG002","title":"Dose Escalation Cohort 3: RO7297089"},{"description":"Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"FG003","title":"Dose Escalation Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.","id":"FG004","title":"Dose Escalation Backfill Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.","id":"FG005","title":"Dose Escalation Cohort 5: RO7297089"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"}],"type":"Study terminated by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"comment":"Alive: In Follow-up","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study consisted of a screening period of up to 28 days and a minimum follow-up period of 90 days after treatment. Following confirmation of eligibility, patients received RO7297089 by intravenous (IV) infusion. Patients were enrolled in two stages: a dose escalation stage and an expansion stage."}